Atara Biotherapeutics Inc ATRA 深 滬
等待開盤 09-24 09:30:00 美东时间
8.56
-0.370
-4.14%
華盛通- 最 高8.95
- 今 開8.92
- 成交量 4.05万股
- 最 低 8.40
- 昨 收 8.93
- 總市值 8.59万
- 52周最高 19.145
- 市盈率 靜 3.33
- 換手率 0.40%
- 52周最低 3.92
- 委 比 13.86%
- 總股本 1.00万
- 歷史最高 1639.00
- 量 比 0.85
- 振 幅 6.16%
- 歷史最低 3.92
- 每 手 1
- 風險率 4.07%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
Rhythm Pharmaceuticals announced the appointment of Manher “AJ” Joshi, M.D., as Chief Medical Officer effective August 17, 2026. Dr. Joshi brings over two decades of leadership experience in drug development, regulatory processes, and lifecycle management. His expertise will support Rhythm’s advancements in next-generation MC4R agonists and its leadership in rare neuroendocrine diseases. Previously, Dr. Joshi served as Chief Development Officer a...
08-17 12:00
Atara Biotherapeutics Q2 EPS $(0.32), Inline, Sales $630.000K Beat $366.667K Estimate
Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.32) per share which met the analyst consensus estimate. This is a 268.42 percent decrease over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $630.000 thousand which beat the ana...
08-13 04:25
Atara Biotherapeutics Q1 EPS $(0.29) Beats $(0.41) Estimate, Sales $516.000K Miss $2.850M Estimate
Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.41) by 27.5 percent. This is a 108.29 percent decrease over earnings of $3.50 per share
05-13 05:31
Atara Biotherapeutics Files Prospectus For Offering $79.3M Common Shares
https://www.sec.gov/Archives/edgar/data/1604464/000119312526219518/atra-424-b5-2026_q2.htm
05-13 04:58
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
Atara surges after FDA meeting on cell therapy
Atara Biotherapeutics (ATRA) climbed nearly 100% on Thursday after the company announced that a recent meeting with the FDA raised prospects for its cell therapy candidate, tabelecleucel, which was re...
05-08 02:13
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Agilon Health (NYSE:AGL) shares moved upwards by 115.7% to $60.08 duri...
05-08 01:05
Atara Biotherapeutics Reports FDA Alignment On Path Forward For Tab-cel Resubmission Following CRL Meeting
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
05-07 20:19
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
WALTHAM, Mass., April 01, 2026 -- Ardelyx, Inc. announced the appointment of Rajani Dinavahi, MD, as Chief Medical Officer. Dr. Dinavahi brings over two decades of experience in healthcare and biotechnology, with expertise in immuno-oncology, autoimmune diseases, metabolic disease, nephrology, and transplantation. She previously served as Chief Medical Officer at Atara Biotherapeutics. Ardelyx's president and CEO, Mike Raab, highlighted her scien...
04-01 12:01
Atara Plans FDA Type A Meeting on EBVALLO
The latest update is out from Atara Biotherapeutics ( ($ATRA) ). On March 12, 2...
03-12 20:37
